571 related articles for article (PubMed ID: 34287770)
1. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
Jedlowski PM; Jedlowski MF; Fazel MT
Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
[TBL] [Abstract][Full Text] [Related]
2. Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System.
Huang L; Liu Y; Li H; Huang W; Geng R; Tang Z; Jiang Y
Int J Med Sci; 2021; 18(9):1946-1952. PubMed ID: 33850463
[No Abstract] [Full Text] [Related]
3. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database.
Béné J; Moulis G; Bennani I; Auffret M; Coupe P; Babai S; Hillaire-Buys D; Micallef J; Gautier S;
Br J Dermatol; 2016 Aug; 175(2):296-301. PubMed ID: 27031194
[TBL] [Abstract][Full Text] [Related]
4. Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase®.
Carnovale C; Mazhar F; Arzenton E; Moretti U; Pozzi M; Mosini G; Leoni O; Scatigna M; Clementi E; Radice S
Expert Opin Drug Saf; 2019 Nov; 18(11):1099-1108. PubMed ID: 31519110
[No Abstract] [Full Text] [Related]
5. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.
Harano Y; Mitamura Y; Jiang P; Fujita T; Babazono A
J Diabetes Investig; 2023 Jun; 14(6):756-766. PubMed ID: 36897510
[TBL] [Abstract][Full Text] [Related]
6. Bullous pemphigoid associated with the use of dipeptidil peptidase-4 inhibitors: analysis from studies based on pharmacovigilance databases.
Molina-Guarneros JA; Sainz-Gil M; Sanz-Fadrique R; García P; Rodríguez-Jiménez P; Navarro-García E; Martin LH
Int J Clin Pharm; 2020 Apr; 42(2):713-720. PubMed ID: 32140915
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Raschi E; Poluzzi E; Koci A; Antonazzo IC; Marchesini G; De Ponti F
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):380-6. PubMed ID: 27067162
[TBL] [Abstract][Full Text] [Related]
8. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials.
Silverii GA; Dicembrini I; Nreu B; Montereggi C; Mannucci E; Monami M
Endocrine; 2020 Sep; 69(3):504-507. PubMed ID: 32236820
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Adverse Events Occurred During Administration of Dipeptidyl Peptidase-4 Inhibitor in Patients with Diabetes Using FDA Adverse Event Reporting System.
Ogura T; Shiraishi C
Clin Drug Investig; 2023 Feb; 43(2):129-140. PubMed ID: 36637688
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
Baksh SN; McAdams-DeMarco M; Segal JB; Alexander GC
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):660-667. PubMed ID: 29655237
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.
Lee H; Chung HJ; Pawar A; Patorno E; Kim DH
JAMA Dermatol; 2020 Oct; 156(10):1107-1114. PubMed ID: 32697283
[TBL] [Abstract][Full Text] [Related]
12. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
Kridin K; Bergman R
JAMA Dermatol; 2018 Oct; 154(10):1152-1158. PubMed ID: 30090931
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events.
Rahman MM; Scalese MJ; Hansen RA
Ann Pharmacother; 2017 Jul; 51(7):563-569. PubMed ID: 28166651
[TBL] [Abstract][Full Text] [Related]
14. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system.
Huang J; Jia Y; Sun S; Meng L
BMC Pharmacol Toxicol; 2020 Sep; 21(1):68. PubMed ID: 32938499
[TBL] [Abstract][Full Text] [Related]
15. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database.
Reolid A; Muñoz-Aceituno E; Rodríguez-Jiménez P; González-Rojano E; Llamas-Velasco M; Fraga J; Daudén E
Int J Dermatol; 2020 Feb; 59(2):197-206. PubMed ID: 31605541
[TBL] [Abstract][Full Text] [Related]
16. Pharmacovigilance study of the association between dipeptidyl peptidase-4 inhibitors and angioedema using the FDA Adverse Event Reporting System (FAERS).
Ohyama K; Shindo J; Takahashi T; Takeuchi H; Hori Y
Sci Rep; 2022 Jul; 12(1):13122. PubMed ID: 35907939
[TBL] [Abstract][Full Text] [Related]
17. Inverse association between DPP-4 inhibitor use and fracture in older adults: A disproportionality analysis of the FAERS and JADER.
Ohyama K; Okamoto T; Hori Y
Int J Clin Pharmacol Ther; 2023 Jan; 61(1):16-23. PubMed ID: 36366967
[TBL] [Abstract][Full Text] [Related]
18. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Aggarwal P
Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
[No Abstract] [Full Text] [Related]
19. Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.
Lee SG; Lee HJ; Yoon MS; Kim DH
JAMA Dermatol; 2019 Feb; 155(2):172-177. PubMed ID: 30624566
[TBL] [Abstract][Full Text] [Related]
20. Association of gynecomastia with antidiabetic medications in older adults: Data mining from different national pharmacovigilance databases.
Ohyama K; Tanaka H; Shindo J; Shibayama M; Iwata M; Hori Y
Int J Clin Pharmacol Ther; 2022 Jan; 60(1):24-31. PubMed ID: 34622771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]